REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC, BCL2, AND BCL6 REARRANGEMENTS
Clinical trials for REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC, BCL2, AND BCL6 REARRANGEMENTS explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC, BCL2, AND BCL6 REARRANGEMENTS trials appear
Sign up with your email to follow new studies for REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC, BCL2, AND BCL6 REARRANGEMENTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail ViPOR targets tough lymphomas in phase II trial
Disease control Recruiting nowThis phase II trial is testing a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in people with certain aggressive B-cell lymphomas that have come back or not responded to treatment. The study aims to see how many patien…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC, BCL2, AND BCL6 REARRANGEMENTS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug duo aims to outsmart tough lymphoma
Disease control Recruiting nowThis trial tests a combination of two drugs, epcoritamab and ibrutinib, for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. Epcoritamab helps immune cells attack lymphoma cells, while ibrutinib blocks signals that help cancer ce…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC, BCL2, AND BCL6 REARRANGEMENTS
Phase: PHASE1, PHASE2 • Sponsor: Yazeed Sawalha • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug tegavivint takes on tough lymphoma in early trial
Disease control Recruiting nowThis early-phase trial is testing a drug called tegavivint in about 18 people with large B-cell lymphoma that has come back or not responded to standard treatments. The drug works by blocking certain enzymes that help cancer cells grow. The main goals are to find a safe dose and …
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC, BCL2, AND BCL6 REARRANGEMENTS
Phase: PHASE1 • Sponsor: Lapo Alinari • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC